Clincosm LogoSign in Get a demo

hepatitis b, chronic

Showing 26 - 50 of 226
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatitis B, Chronic Trial in Changchun (drug, other, combination product)

Not yet recruiting
  • Hepatitis B, Chronic
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Jul 29, 2022

Hepatitis B, Chronic Trial in Beijing, Changchun (VIR-2218, Placebo)

Completed
  • Hepatitis B, Chronic
  • Beijing, Beijing, China
  • +1 more
Jul 26, 2022

Hepatitis B, Chronic, Fibrosis, Liver, Diabetes, Type 2 Trial in Seoul (Pioglitazone 15 Mg Oral Tablet, Evogliptin 5mg)

Active, not recruiting
  • Hepatitis B, Chronic
  • +2 more
  • Pioglitazone 15 Mg Oral Tablet
  • Evogliptin 5mg
  • Seoul, Korea, Republic of
  • +3 more
Jul 21, 2022

Healthy Volunteers, Hepatitis B, Chronic Trial in Changchun (ZM-H1505R, ZM-H1505R Placebo)

Completed
  • Healthy Volunteers
  • Hepatitis B, Chronic
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Jul 20, 2022

Hepatitis B, Chronic Trial in Worldwide (Midazolam, Placebo, RO7049389)

Completed
  • Hepatitis B, Chronic
  • Herston, Queensland, Australia
  • +20 more
Jul 7, 2022

Hepatitis B, Chronic Trial in Worldwide (Cetrelimab, Placebo)

Recruiting
  • Hepatitis B, Chronic
  • Edegem, Belgium
  • +13 more
Jul 5, 2022

Hepatitis B, Chronic Trial in New York, Philadelphia (VPN, TM)

Completed
  • Hepatitis B, Chronic
  • VPN
  • TM
  • New York, New York
  • +1 more
Jun 24, 2022

Hepatitis B, Chronic Trial in Shanghai, Beijing (Hydronidone, Placebo, Entecavir)

Completed
  • Hepatitis B, Chronic
  • Shanghai, Shanghai, China
  • +1 more
Jun 21, 2022

Hepatitis B, Chronic, Lipid Disorder Trial in Wuhan (oral Tenofovir Amibufenamide 25mg each day, lipid lowering drugs (e.g.

Enrolling by invitation
  • Hepatitis B, Chronic
  • Lipid Disorder
  • oral Tenofovir Amibufenamide 25mg each day
  • lipid lowering drugs (e.g. Atorvastatin and amlodipine.)
  • Wuhan, Hubei, China
    Wuhan Union hosipital
May 25, 2022

Hepatitis B, Chronic Trial in Guangzhou, Changchun (Freethiadine tablets(part I), Freethiadine tablets (part II), Freethiadine

Recruiting
  • Hepatitis B, Chronic
  • Freethiadine tablets(part I)
  • +3 more
  • Guangzhou, Guangdong, China
  • +1 more
May 20, 2022

Combination of DPMAS and Low Volume PE for HBV Related ACLF

Recruiting
  • Hepatitis B, Chronic
  • Acute-On-Chronic Liver Failure
  • Artificial liver support system
  • Guangzhou, Guangdong, China
    Third Affiliated Hospital of Sun Yat-sen University
May 14, 2022

Hepatitis B, Chronic Trial in Daegu, Seoul, Ulsan (Stop group)

Recruiting
  • Hepatitis B, Chronic
  • Stop group
  • Daegu, Korea, Republic of
  • +9 more
May 11, 2022

Hepatitis B, Chronic Trial in Gothenburg (Stopping)

Not yet recruiting
  • Hepatitis B, Chronic
  • Stopping
  • Gothenburg, VGR, Sweden
    Infectious Diseases Clinic, Sahlgrenska University Hospital
Apr 13, 2022

Hepatitis B, Chronic Trial in Beijing (Granulocyte Macrophage-colony Stimulating Factor, Entecavir)

Terminated
  • Hepatitis B, Chronic
  • Granulocyte Macrophage-colony Stimulating Factor
  • Entecavir
  • Beijing, Beijing, China
    302 Military Hospital
Mar 9, 2022

Hepatitis B, Chronic, Adherence, Medication, Quality of Life Trial (effectiveness of education)

Not yet recruiting
  • Hepatitis B, Chronic
  • +2 more
  • effectiveness of education
  • (no location specified)
Mar 17, 2022

Hepatitis B, Chronic Trial in Worldwide (administration of SLGN in arm C, Discontinuation of NUC treatment in arms B and C)

Recruiting
  • Hepatitis B, Chronic
  • administration of SLGN in arm C
  • Discontinuation of NUC treatment in arms B and C
  • Lyon, France
  • +7 more
Mar 11, 2022

Hepatitis B, Chronic, Hepatic Steatosis Trial (High Intensity Interval Training)

Not yet recruiting
  • Hepatitis B, Chronic
  • Hepatic Steatosis
  • High Intensity Interval Training
  • (no location specified)
Mar 3, 2022

Hepatitis B, Chronic Trial in Worldwide (BRII-835 (VIR-2218), BRII-179 (VBI-2601) with IFN-a, BRII-179 (VBI-2601))

Active, not recruiting
  • Hepatitis B, Chronic
  • BRII-835 (VIR-2218)
  • +2 more
  • Kingswood, New South Wales, Australia
  • +27 more
Mar 1, 2022

Hepatitis B, Chronic Trial in China (Tenofovir disoproxil fumarate)

Completed
Has Results
  • Hepatitis B, Chronic
  • Tenofovir disoproxil fumarate
  • Guangzhou, Guangdong, China
  • +18 more
Nov 26, 2021

Hepatitis B, Chronic Trial in Worldwide (ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation,

Recruiting
  • Hepatitis B, Chronic
  • ChAd155-hIi-HBV low dose formulation
  • +6 more
  • Antwerpen, Belgium
  • +35 more
Jan 28, 2022

Hepatitis B, Chronic Trial in Guangzhou (ASC42 10mg, ASC42 15mg, ih PEG-IFN a-2a)

Recruiting
  • Hepatitis B, Chronic
  • ASC42 10mg
  • +4 more
  • Guangzhou, Guangdong, China
    NanFang Hospital of Southern Medical University
Jan 13, 2022

The HOPE Study: Characterizing Patients With Hepatitis B and C

Recruiting
  • Hepatitis B， Chronic
  • Hepatitis C
  • Blood draws
  • +4 more
  • Washington, District of Columbia
  • +3 more
Jan 3, 2022

Hepatitis B, Chronic, Mother to Child Transmission Trial in China (antiviral prophylaxis with Tenofovir Alafenamide Fumarate)

Recruiting
  • Hepatitis B, Chronic
  • Mother to Child Transmission
  • antiviral prophylaxis with Tenofovir Alafenamide Fumarate
  • Chang chun, China
  • +12 more
Dec 15, 2021

Mother-to-child Transmission of HBV in China

Recruiting
  • Hepatitis B, Chronic
  • Mother to Child Transmission
  • comprehensive management algorithm for preventing mother-to-child transmission of HBV
  • Guangzhou, Guangdong, China
  • +14 more
Dec 13, 2021

Entecavir Versus Tenofovir on HBV DNA Level in Peripheral Blood

Not yet recruiting
  • Hepatitis B, Chronic
  • Detection of HBV-DNA in Peripheral Blood Mononuclear cells
  • (no location specified)
Dec 13, 2021